Invasion as target for therapy of glioblastoma multiforme

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1836, Issue 2, 2013, Pages 236-244

  Vehlow, Anne ^a   Cordes, Nils ^a,b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

Author keywords

Extracellular matrix; Glioblastoma multiforme; Integrins; Invasion; Proteases; Radiochemotherapy

Indexed keywords

CATHEPSIN B; CELL SURFACE RECEPTOR; CYSTEINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; GELATINASE B; PHOSPHATASE; PROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CELL INVASION; CELL MOTILITY; EPIGENETICS; EXTRACELLULAR MATRIX; GENE MUTATION; GENETIC HETEROGENEITY; GLIOBLASTOMA; HUMAN; PRIORITY JOURNAL; REVIEW; TUMOR CELL; TUMOR MICROENVIRONMENT;

EXTRACELLULAR MATRIX; GLIOBLASTOMA MULTIFORME; INTEGRINS; INVASION; PROTEASES; RADIOCHEMOTHERAPY;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL MOVEMENT; GLIOBLASTOMA; HUMANS; NEOPLASM INVASIVENESS;

EID: 84882803879     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2013.07.001     Document Type: Review

References (180)

1. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., Scheithauer B.W., Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007, 114:97.
2. Becker K.P., Yu J. Status quo - standard-of-care medical and radiation therapy for glioblastoma. Cancer J. 2012, 18:12.
3. Lima F.R., Kahn S.A., Soletti R.C., Biasoli D., Alves T., da Fonseca A.C., Garcia C., Romao L., Brito J., Holanda-Afonso R., Faria J., Borges H., Moura-Neto V. Glioblastoma: therapeutic challenges, what lies ahead. Biochim. Biophys. Acta 2012, 1826:338.
4. Guckenberger M., Mayer M., Buttmann M., Vince G.H., Sweeney R.A., Flentje M. Prolonged survival when temozolomide is added to accelerated radiotherapy for glioblastoma multiforme. Strahlenther. Onkol. 2011, 187:548.
5. Stupp R., Hegi M.E., Mason W.P., van den Bent M.J., Taphoorn M.J., Janzer R.C., Ludwin S.K., Allgeier A., Fisher B., Belanger K., Hau P., Brandes A.A., Gijtenbeek J., Marosi C., Vecht C.J., Mokhtari K., Wesseling P., Villa S., Eisenhauer E., Gorlia T., Weller M., Lacombe D., Cairncross J.G., Mirimanoff R.O. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009, 10:459.
6. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., Curschmann J., Janzer R.C., Ludwin S.K., Gorlia T., Allgeier A., Lacombe D., Cairncross J.G., Eisenhauer E., Mirimanoff R.O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352:987.
7. Weller M., Stupp R., Hegi M., Wick W. Individualized targeted therapy for glioblastoma: fact or fiction?. Cancer J. 2012, 18:40.
8. Verhaak R.G., Hoadley K.A., Purdom E., Wang V., Qi Y., Wilkerson M.D., Miller C.R., Ding L., Golub T., Mesirov J.P., Alexe G., Lawrence M., O'Kelly M., Tamayo P., Weir B.A., Gabriel S., Winckler W., Gupta S., Jakkula L., Feiler H.S., Hodgson J.G., James C.D., Sarkaria J.N., Brennan C., Kahn A., Spellman P.T., Wilson R.K., Speed T.P., Gray J.W., Meyerson M., Getz G., Perou C.M., Hayes D.N. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17:98.
9. Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Siu I.M., Gallia G.L., Olivi A., McLendon R., Rasheed B.A., Keir S., Nikolskaya T., Nikolsky Y., Busam D.A., Tekleab H., Diaz L.A., Hartigan J., Smith D.R., Strausberg R.L., Marie S.K., Shinjo S.M., Yan H., Riggins G.J., Bigner D.D., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., Kinzler K.W. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807.
10. T.C.G.A.R.Network Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061.
11. Furnari F.B., Fenton T., Bachoo R.M., Mukasa A., Stommel J.M., Stegh A., Hahn W.C., Ligon K.L., Louis D.N., Brennan C., Chin L., DePinho R.A., Cavenee W.K. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007, 21:2683.
12. Phillips H.S., Kharbanda S., Chen R., Forrest W.F., Soriano R.H., Wu T.D., Misra A., Nigro J.M., Colman H., Soroceanu L., Williams P.M., Modrusan Z., Feuerstein B.G., Aldape K. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006, 9:157.
13. Dunn G.P., Rinne M.L., Wykosky J., Genovese G., Quayle S.N., Dunn I.F., Agarwalla P.K., Chheda M.G., Campos B., Wang A., Brennan C., Ligon K.L., Furnari F., Cavenee W.K., Depinho R.A., Chin L., Hahn W.C. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev. 2012, 26:756.
14. Silber J.R., Bobola M.S., Blank A., Chamberlain M.C. O(6)-methylguanine-DNA methyltransferase in glioma therapy: promise and problems. Biochim. Biophys. Acta 2012, 1826:71.
15. Hegi M.E., Diserens A.C., Gorlia T., Hamou M.F., de Tribolet N., Weller M., Kros J.M., Hainfellner J.A., Mason W., Mariani L., Bromberg J.E., Hau P., Mirimanoff R.O., Cairncross J.G., Janzer R.C., Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 2005, 352:997.
16. Hegi M.E., Diserens A.C., Godard S., Dietrich P.Y., Regli L., Ostermann S., Otten P., Van Melle G., de Tribolet N., Stupp R. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin. Cancer Res. 2004, 10:1871.
17. Esteller M., Garcia-Foncillas J., Andion E., Goodman S.N., Hidalgo O.F., Vanaclocha V., Baylin S.B., Herman J.G. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 2000, 343:1350.
18. Giese A., Bjerkvig R., Berens M.E., Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J. Clin. Oncol. 2003, 21:1624.
19. Alexander S., Friedl P. Cancer invasion and resistance: interconnected processes of disease progression and therapy failure. Trends Mol. Med. 2012, 18:13.
20. Friedl P., Wolf K. Plasticity of cell migration: a multiscale tuning model. J. Cell Biol. 2010, 188:11.
21. Zhong J., Paul A., Kellie S.J., O'Neill G.M. Mesenchymal migration as a therapeutic target in glioblastoma. J. Oncol. 2010, 2010:430142.
22. Cordes N., Meineke V. Cell adhesion-mediated radioresistance (CAM-RR) extracellular matrix-dependent improvement of cell survival in human tumor and normal cells in vitro. Strahlenther. Onkol. 2003, 179:337.
23. Eke I., Storch K., Kastner I., Vehlow A., Faethe C., Mueller-Klieser W., Taucher-Scholz G., Temme A., Schackert G., Cordes N. Three-dimensional invasion of human glioblastoma cells remains unchanged by X-ray and carbon ion irradiation in vitro. Int. J. Radiat. Oncol. Biol. Phys. 2012, 84:e515.
24. Eke I., Cordes N. Radiobiology goes 3D: how ECM and cell morphology impact on cell survival after irradiation. Radiother. Oncol. 2011, 99:271.
25. Westphal M., Lamszus K. The neurobiology of gliomas: from cell biology to the development of therapeutic approaches. Nat. Rev. Neurosci. 2011, 12:495.
26. Bellail A.C., Hunter S.B., Brat D.J., Tan C., Van Meir E.G. Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int. J. Biochem. Cell Biol. 2004, 36:1046.
27. Mentlein R., Hattermann K., Held-Feindt J. Lost in disruption: role of proteases in glioma invasion and progression. Biochim. Biophys. Acta 2012, 1825:178.
28. Nakada M., Nakada S., Demuth T., Tran N.L., Hoelzinger D.B., Berens M.E. Molecular targets of glioma invasion. Cell Mol. Life Sci. 2007, 64:458.
29. Rao J.S. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat. Rev. Cancer 2003, 3:489.
30. Levin V.A., Phuphanich S., Yung W.K., Forsyth P.A., Maestro R.D., Perry J.R., Fuller G.N., Baillet M. Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation. J. Neurooncol. 2006, 78:295.
31. Hynes R.O. The extracellular matrix: not just pretty fibrils. Science 2009, 326:1216.
32. Chintala S.K., Rao J.K. Invasion of human glioma: role of extracellular matrix proteins. Front. Biosci. 1996, 1:d324.
33. Paulus W., Baur I., Beutler A.S., Reeves S.A. Diffuse brain invasion of glioma cells requires beta 1 integrins. Lab. Invest. 1996, 75:819.
34. Nicholson C., Sykova E. Extracellular space structure revealed by diffusion analysis. Trends Neurosci. 1998, 21:207.
35. Novak U., Kaye A.H. Extracellular matrix and the brain: components and function. J. Clin. Neurosci. 2000, 7:280.
36. Giese A., Westphal M. Glioma invasion in the central nervous system. Neurosurgery 1996, 39:235. (discussion 250-232).
37. Chintala S.K., Sawaya R., Gokaslan Z.L., Fuller G., Rao J.S. Immunohistochemical localization of extracellular matrix proteins in human glioma, both in vivo and in vitro. Cancer Lett. 1996, 101:107.
38. Previtali S., Quattrini A., Nemni R., Truci G., Ducati A., Wrabetz L., Canal N. Alpha6 beta4 and alpha6 beta1 integrins in astrocytomas and other CNS tumors. J. Neuropathol. Exp. Neurol. 1996, 55:456.
39. Gladson C.L., Cheresh D.A. Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. J. Clin. Invest. 1991, 88:1924.
40. Ogawa K., Oguchi M., Nakashima Y., Yamabe H. Distribution of collagen type IV in brain tumors: an immunohistochemical study. J. Neurooncol. 1989, 7:357.
41. Paulus W., Roggendorf W., Schuppan D. Immunohistochemical investigation of collagen subtypes in human glioblastomas. Virchows Arch. A Pathol. Anat. Histopathol. 1988, 413:325.
42. Bellon G., Caulet T., Cam Y., Pluot M., Poulin G., Pytlinska M., Bernard M.H. Immunohistochemical localisation of macromolecules of the basement membrane and extracellular matrix of human gliomas and meningiomas. Acta Neuropathol. 1985, 66:245.
43. McComb R.D., Bigner D.D. Immunolocalization of laminin in neoplasms of the central and peripheral nervous systems. J. Neuropathol. Exp. Neurol. 1985, 44:242.
44. Jones T.R., Ruoslahti E., Schold S.C., Bigner D.D. Fibronectin and glial fibrillary acidic protein expression in normal human brain and anaplastic human gliomas. Cancer Res. 1982, 42:168.
45. Paetau A., Mellstrom K., Vaheri A., Haltia M. Distribution of a major connective tissue protein, fibronectin, in normal and neoplastic human nervous tissue. Acta Neuropathol. 1980, 51:47.
46. Ohnishi T., Hiraga S., Izumoto S., Matsumura H., Kanemura Y., Arita N., Hayakawa T. Role of fibronectin-stimulated tumor cell migration in glioma invasion in vivo: clinical significance of fibronectin and fibronectin receptor expressed in human glioma tissues. Clin. Exp. Metastasis 1998, 16:729.
47. Tysnes B.B., Mahesparan R., Thorsen F., Haugland H.K., Porwol T., Enger P.O., Lund-Johansen M., Bjerkvig R. Laminin expression by glial fibrillary acidic protein positive cells in human gliomas. Int. J. Dev. Neurosci. 1999, 17:531.
48. Knott J.C., Mahesparan R., Garcia-Cabrera I., Bolge Tysnes B., Edvardsen K., Ness G.O., Mork S., Lund-Johansen M., Bjerkvig R. Stimulation of extracellular matrix components in the normal brain by invading glioma cells. Int. J. Cancer 1998, 75:864.
49. Pedersen P.H., Marienhagen K., Mork S., Bjerkvig R. Migratory pattern of fetal rat brain cells and human glioma cells in the adult rat brain. Cancer Res. 1993, 53:5158.
50. Giordana M.T., Germano I., Giaccone G., Mauro A., Migheli A., Schiffer D. The distribution of laminin in human brain tumors: an immunohistochemical study. Acta Neuropathol. 1985, 67:51.
51. Bello L., Francolini M., Marthyn P., Zhang J., Carroll R.S., Nikas D.C., Strasser J.F., Villani R., Cheresh D.A., Black P.M. Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery 2001, 49:380. (discussion 390).
52. Bourdon M.A., Wikstrand C.J., Furthmayr H., Matthews T.J., Bigner D.D. Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res. 1983, 43:2796.
53. Senner V., Ratzinger S., Mertsch S., Grassel S., Paulus W. Collagen XVI expression is upregulated in glioblastomas and promotes tumor cell adhesion. FEBS Lett. 2008, 582:3293.
54. Tatenhorst L., Senner V., Puttmann S., Paulus W. Regulators of G-protein signaling 3 and 4 (RGS3, RGS4) are associated with glioma cell motility. J. Neuropathol. Exp. Neurol. 2004, 63:210.
55. Bauer R., Ratzinger S., Wales L., Bosserhoff A., Senner V., Grifka J., Grassel S. Inhibition of collagen XVI expression reduces glioma cell invasiveness. Cell. Physiol. Biochem. 2011, 27:217.
56. Bouterfa H., Darlapp A.R., Klein E., Pietsch T., Roosen K., Tonn J.C. Expression of different extracellular matrix components in human brain tumor and melanoma cells in respect to variant culture conditions. J. Neurooncol. 1999, 44:23.
57. Paulus W., Huettner C., Tonn J.C. Collagens, integrins and the mesenchymal drift in glioblastomas: a comparison of biopsy specimens, spheroid and early monolayer cultures. Int. J. Cancer 1994, 58:841.
58. Bjerkvig R., Laerum O.D., Rucklidge G.J. Immunocytochemical characterization of extracellular matrix proteins expressed by cultured glioma cells. Cancer Res. 1989, 49:5424.
59. Mahesparan R., Read T.A., Lund-Johansen M., Skaftnesmo K.O., Bjerkvig R., Engebraaten O. Expression of extracellular matrix components in a highly infiltrative in vivo glioma model. Acta Neuropathol. 2003, 105:49.
60. Baldwin J.R., McKeever P.E., Booker T.R. Products of cultured neuroglial cells: II. The production of fibronectin by C6 glioma cells. Neurochem. Res. 1985, 10:601.
61. Bigner D.D., Bigner S.H., Ponten J., Westermark B., Mahaley M.S., Ruoslahti E., Herschman H., Eng L.F., Wikstrand C.J. Heterogeneity of genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas. J. Neuropathol. Exp. Neurol. 1981, 40:201.
62. Savaraj N., Wu C., Landy H., Wangpaijit M., Wei Y., Kuo M.T., Robles C., Furst A.J., Lampidis T., Feun L. Procollagen alpha 1 type 1: a potential aide in histopathological grading of glioma. Cancer Invest. 2005, 23:577.
63. Ghahary A., Bhatnagar R., Price K., Forsyth N.L., Shen Y.J., Tredget T.E., Malhotra S.K. Rat glioma cell lines C6 and 9L synthesize type 1 collagen in vitro. Brain Res. Bull. 1992, 28:47.
64. Han J., Daniel J.C. Biosynthesis of type VI collagen by glioblastoma cells and possible function in cell invasion of three-dimensional matrices. Conn. Tissue Res. 1995, 31:161.
65. Han J., Daniel J.C., Pappas G.D. Expression of type VI collagen during glioblastoma cell invasion in brain tissue cultures. Cancer Lett. 1995, 88:127.
66. Gladson C.L., Wilcox J.N., Sanders L., Gillespie G.Y., Cheresh D.A. Cerebral microenvironment influences expression of the vitronectin gene in astrocytic tumors. J. Cell Sci. 1995, 108(Pt 3):947.
67. Kochi N., Tani E., Morimura T., Itagaki T. Immunohistochemical study of fibronectin in human glioma and meningioma. Acta Neuropathol. 1983, 59:119.
68. Ljubimova J.Y., Lakhter A.J., Loksh A., Yong W.H., Riedinger M.S., Miner J.H., Sorokin L.M., Ljubimov A.V., Black K.L. Overexpression of alpha4 chain-containing laminins in human glial tumors identified by gene microarray analysis. Cancer Res. 2001, 61:5601.
69. Ljubimova J.Y., Fujita M., Khazenzon N.M., Ljubimov A.V., Black K.L. Changes in laminin isoforms associated with brain tumor invasion and angiogenesis. Front. Biosci. 2006, 11:81.
70. Ljubimova J.Y., Fugita M., Khazenzon N.M., Das A., Pikul B.B., Newman D., Sekiguchi K., Sorokin L.M., Sasaki T., Black K.L. Association between laminin-8 and glial tumor grade, recurrence, and patient survival. Cancer 2004, 101:604.
71. Khazenzon N.M., Ljubimov A.V., Lakhter A.J., Fujita M., Fujiwara H., Sekiguchi K., Sorokin L.M., Petajaniemi N., Virtanen I., Black K.L., Ljubimova J.Y. Antisense inhibition of laminin-8 expression reduces invasion of human gliomas in vitro. Mol. Cancer Ther. 2003, 2:985.
72. Mohanam S., Gladson C.L., Rao C.N., Rao J.S. Biological significance of the expression of urokinase-type plasminogen activator receptors (uPARs) in brain tumors. Front. Biosci. 1999, 4:D178.
73. Colin C., Voutsinos-Porche B., Nanni I., Fina F., Metellus P., Intagliata D., Baeza N., Bouvier C., Delfino C., Loundou A., Chinot O., Lah T., Kos J., Martin P.M., Ouafik L., Figarella-Branger D. High expression of cathepsin B and plasminogen activator inhibitor type-1 are strong predictors of survival in glioblastomas. Acta Neuropathol. 2009, 118:745.
74. Zhang X., Bu X.Y., Zhen H.N., Fei Z., Zhang J.N., Fu L.A. Expression and localisation of urokinase-type plasminogen activator gene in gliomas. J. Clin. Neurosci. 2000, 7:116.
75. Yamamoto M., Sawaya R., Mohanam S., Rao V.H., Bruner J.M., Nicolson G.L., Rao J.S. Expression and localization of urokinase-type plasminogen activator receptor in human gliomas. Cancer Res. 1994, 54:5016.
76. Gladson C.L., Pijuan-Thompson V., Olman M.A., Gillespie G.Y., Yacoub I.Z. Up-regulation of urokinase and urokinase receptor genes in malignant astrocytoma. Am. J. Pathol. 1995, 146:1150.
77. Arai Y., Kubota T., Nakagawa T., Kabuto M., Sato K., Kobayashi H. Production of urokinase-type plasminogen activator (u-PA) and plasminogen activator inhibitor-1 (PAI-1) in human brain tumours. Acta Neurochir. (Wien) 1998, 140:377. (discussion 385-376).
78. Yamamoto M., Sawaya R., Mohanam S., Bindal A.K., Bruner J.M., Oka K., Rao V.H., Tomonaga M., Nicolson G.L., Rao J.S. Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo. Cancer Res. 1994, 54:3656.
79. Raghu H., Gondi C.S., Dinh D.H., Gujrati M., Rao J.S. Specific knockdown of uPA/uPAR attenuates invasion in glioblastoma cells and xenografts by inhibition of cleavage and trafficking of Notch-1 receptor. Mol. Cancer 2011, 10:130.
80. Gondi C.S., Lakka S.S., Yanamandra N., Olivero W.C., Dinh D.H., Gujrati M., Tung C.H., Weissleder R., Rao J.S. Adenovirus-mediated expression of antisense urokinase plasminogen activator receptor and antisense cathepsin B inhibits tumor growth, invasion, and angiogenesis in gliomas. Cancer Res. 2004, 64:4069.
81. Gondi C.S., Lakka S.S., Yanamandra N., Siddique K., Dinh D.H., Olivero W.C., Gujrati M., Rao J.S. Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis. Oncogene 2003, 22:5967.
82. Mori T., Abe T., Wakabayashi Y., Hikawa T., Matsuo K., Yamada Y., Kuwano M., Hori S. Up-regulation of urokinase-type plasminogen activator and its receptor correlates with enhanced invasion activity of human glioma cells mediated by transforming growth factor-alpha or basic fibroblast growth factor. J. Neurooncol. 2000, 46:115.
83. Mohanam S., Chintala S.K., Go Y., Bhattacharya A., Venkaiah B., Boyd D., Gokaslan Z.L., Sawaya R., Rao J.S. In vitro inhibition of human glioblastoma cell line invasiveness by antisense uPA receptor. Oncogene 1997, 14:1351.
84. Rao J.S., Steck P.A., Tofilon P., Boyd D., Ali-Osman F., Stetler-Stevenson W.G., Liotta L.A., Sawaya R. Role of plasminogen activator and of 92-KDa type IV collagenase in glioblastoma invasion using an in vitro matrigel model. J. Neurooncol. 1994, 18:129.
85. Mohanam S., Sawaya R., McCutcheon I., Ali-Osman F., Boyd D., Rao J.S. Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody. Cancer Res. 1993, 53:4143.
86. Go Y., Chintala S.K., Mohanam S., Gokaslan Z., Venkaiah B., Bjerkvig R., Oka K., Nicolson G.L., Sawaya R., Rao J.S. Inhibition of in vivo tumorigenicity and invasiveness of a human glioblastoma cell line transfected with antisense uPAR vectors. Clin. Exp. Metastasis 1997, 15:440.
87. Levicar N., Strojnik T., Kos J., Dewey R.A., Pilkington G.J., Lah T.T. Lysosomal enzymes, cathepsins in brain tumour invasion. J. Neurooncol. 2002, 58:21.
88. McCormick D. Secretion of cathepsin B by human gliomas in vitro. Neuropathol. Appl. Neurobiol. 1993, 19:146.
89. Mikkelsen T., Yan P.S., Ho K.L., Sameni M., Sloane B.F., Rosenblum M.L. Immunolocalization of cathepsin B in human glioma: implications for tumor invasion and angiogenesis. J. Neurosurg. 1995, 83:285.
90. Sivaparvathi M., Sawaya R., Wang S.W., Rayford A., Yamamoto M., Liotta L.A., Nicolson G.L., Rao J.S. Overexpression and localization of cathepsin B during the progression of human gliomas. Clin. Exp. Metastasis 1995, 13:49.
91. Rempel S.A., Rosenblum M.L., Mikkelsen T., Yan P.S., Ellis K.D., Golembieski W.A., Sameni M., Rozhin J., Ziegler G., Sloane B.F. Cathepsin B expression and localization in glioma progression and invasion. Cancer Res. 1994, 54:6027.
92. Demchik L.L., Sameni M., Nelson K., Mikkelsen T., Sloane B.F. Cathepsin B and glioma invasion. Int. J. Dev. Neurosci. 1999, 17:483.
93. Strojnik T., Kos J., Zidanik B., Golouh R., Lah T. Cathepsin B immunohistochemical staining in tumor and endothelial cells is a new prognostic factor for survival in patients with brain tumors. Clin. Cancer Res. 1999, 5:559.
94. Lakka S.S., Gondi C.S., Yanamandra N., Olivero W.C., Dinh D.H., Gujrati M., Rao J.S. Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene 2004, 23:4681.
95. Mohanam S., Jasti S.L., Kondraganti S.R., Chandrasekar N., Lakka S.S., Kin Y., Fuller G.N., Yung A.W., Kyritsis A.P., Dinh D.H., Olivero W.C., Gujrati M., Ali-Osman F., Rao J.S. Down-regulation of cathepsin B expression impairs the invasive and tumorigenic potential of human glioblastoma cells. Oncogene 2001, 20:3665.
96. Nakada M., Okada Y., Yamashita J. The role of matrix metalloproteinases in glioma invasion. Front. Biosci. 2003, 8:e261.
97. Hagemann C., Anacker J., Ernestus R.I., Vince G.H. A complete compilation of matrix metalloproteinase expression in human malignant gliomas. World J. Clin. Oncol. 2012, 3:67.
98. Forsyth P.A., Wong H., Laing T.D., Rewcastle N.B., Morris D.G., Muzik H., Leco K.J., Johnston R.N., Brasher P.M., Sutherland G., Edwards D.R. Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br. J. Cancer 1999, 79:1828.
99. Lampert K., Machein U., Machein M.R., Conca W., Peter H.H., Volk B. Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumors. Am. J. Pathol. 1998, 153:429.
100. Sawaya R.E., Yamamoto M., Gokaslan Z.L., Wang S.W., Mohanam S., Fuller G.N., McCutcheon I.E., Stetler-Stevenson W.G., Nicolson G.L., Rao J.S. Expression and localization of 72kDa type IV collagenase (MMP-2) in human malignant gliomas in vivo. Clin. Exp. Metastasis 1996, 14:35.
101. Nakano A., Tani E., Miyazaki K., Yamamoto Y., Furuyama J. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas. J. Neurosurg. 1995, 83:298.
102. Deryugina E.I., Bourdon M.A., Luo G.X., Reisfeld R.A., Strongin A. Matrix metalloproteinase-2 activation modulates glioma cell migration. J. Cell Sci. 1997, 110(Pt 19):2473.
103. Nakada M., Nakamura H., Ikeda E., Fujimoto N., Yamashita J., Sato H., Seiki M., Okada Y. Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors. Am. J. Pathol. 1999, 154:417.
104. Yamamoto M., Mohanam S., Sawaya R., Fuller G.N., Seiki M., Sato H., Gokaslan Z.L., Liotta L.A., Nicolson G.L., Rao J.S. Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro. Cancer Res. 1996, 56:384.
105. Kesanakurti D., Chetty C., Dinh D.H., Gujrati M., Rao J.S. Role of MMP-2 in the regulation of IL-6/Stat3 survival signaling via interaction with alpha5beta1 integrin in glioma. Oncogene 2013, 32:327.
106. Kesanakurti D., Chetty C., Rajasekhar Maddirela D., Gujrati M., Rao J.S. Functional cooperativity by direct interaction between PAK4 and MMP-2 in the regulation of anoikis resistance, migration and invasion in glioma. Cell Death Dis. 2012, 3:e445.
107. Badiga A.V., Chetty C., Kesanakurti D., Are D., Gujrati M., Klopfenstein J.D., Dinh D.H., Rao J.S. MMP-2 siRNA inhibits radiation-enhanced invasiveness in glioma cells. PLoS One 2011, 6:e20614.
108. Choe G., Park J.K., Jouben-Steele L., Kremen T.J., Liau L.M., Vinters H.V., Cloughesy T.F., Mischel P.S. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype. Clin. Cancer Res. 2002, 8:2894.
109. Raithatha S.A., Muzik H., Muzik H., Rewcastle N.B., Johnston R.N., Edwards D.R., Forsyth P.A. Localization of gelatinase-A and gelatinase-B mRNA and protein in human gliomas. Neuro Oncol. 2000, 2:145.
110. Rao J.S., Yamamoto M., Mohaman S., Gokaslan Z.L., Fuller G.N., Stetler-Stevenson W.G., Rao V.H., Liotta L.A., Nicolson G.L., Sawaya R.E. Expression and localization of 92kDa type IV collagenase/gelatinase B (MMP-9) in human gliomas. Clin. Exp. Metastasis 1996, 14:12.
111. Nakagawa T., Kubota T., Kabuto M., Sato K., Kawano H., Hayakawa T., Okada Y. Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors. J. Neurosurg. 1994, 81:69.
112. Rao J.S., Steck P.A., Mohanam S., Stetler-Stevenson W.G., Liotta L.A., Sawaya R. Elevated levels of M(r) 92,000 type IV collagenase in human brain tumors. Cancer Res. 1993, 53:2208.
113. Kondraganti S., Mohanam S., Chintala S.K., Kin Y., Jasti S.L., Nirmala C., Lakka S.S., Adachi Y., Kyritsis A.P., Ali-Osman F., Sawaya R., Fuller G.N., Rao J.S. Selective suppression of matrix metalloproteinase-9 in human glioblastoma cells by antisense gene transfer impairs glioblastoma cell invasion. Cancer Res. 2000, 60:6851.
114. Lakka S.S., Rajan M., Gondi C., Yanamandra N., Chandrasekar N., Jasti S.L., Adachi Y., Siddique K., Gujrati M., Olivero W., Dinh D.H., Kouraklis G., Kyritsis A.P., Rao J.S. Adenovirus-mediated expression of antisense MMP-9 in glioma cells inhibits tumor growth and invasion. Oncogene 2002, 21:8011.
115. Sawaya R., Go Y., Kyritisis A.P., Uhm J., Venkaiah B., Mohanam S., Gokaslan Z.L., Rao J.S. Elevated levels of Mr 92,000 type IV collagenase during tumor growth in vivo. Biochem. Biophys. Res. Commun. 1998, 251:632.
116. Cordes N., Hansmeier B., Beinke C., Meineke V., van Beuningen D. Irradiation differentially affects substratum-dependent survival, adhesion, and invasion of glioblastoma cell lines. Br. J. Cancer 2003, 89:2122.
117. Park C.M., Park M.J., Kwak H.J., Lee H.C., Kim M.S., Lee S.H., Park I.C., Rhee C.H., Hong S.I. Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/epidermal growth factor receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways. Cancer Res. 2006, 66:8511.
118. Wick W., Wick A., Schulz J.B., Dichgans J., Rodemann H.P., Weller M. Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase. Cancer Res. 2002, 62:1915.
119. Lee W.H., Warrington J.P., Sonntag W.E., Lee Y.W. Irradiation alters MMP-2/TIMP-2 system and collagen type IV degradation in brain. Int. J. Radiat. Oncol. Biol. Phys. 2012, 82:1559.
120. Wild-Bode C., Weller M., Rimner A., Dichgans J., Wick W. Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. Cancer Res. 2001, 61:2744.
121. Trog D., Yeghiazaryan K., Fountoulakis M., Friedlein A., Moenkemann H., Haertel N., Schueller H., Breipohl W., Schild H., Leppert D., Golubnitschaja O. Pro-invasive gene regulating effect of irradiation and combined temozolomide-radiation treatment on surviving human malignant glioma cells. Eur. J. Pharmacol. 2006, 542:8.
122. Giannopoulou E., Katsoris P., Hatziapostolou M., Kardamakis D., Kotsaki E., Polytarchou C., Parthymou A., Papaioannou S., Papadimitriou E. X-rays modulate extracellular matrix in vivo. Int. J. Cancer 2001, 94:690.
123. Hynes R.O. Integrins: bidirectional, allosteric signaling machines. Cell 2002, 110:673.
124. Humphries J.D., Byron A., Humphries M.J. Integrin ligands at a glance. J. Cell Sci. 2006, 119:3901.
125. Janouskova H., Maglott A., Leger D.Y., Bossert C., Noulet F., Guerin E., Guenot D., Pinel S., Chastagner P., Plenat F., Entz-Werle N., Lehmann-Che J., Godet J., Martin S., Teisinger J., Dontenwill M. Integrin alpha5beta1 plays a critical role in resistance to temozolomide by interfering with the p53 pathway in high-grade glioma. Cancer Res. 2012, 72:3463.
126. Riemenschneider M.J., Mueller W., Betensky R.A., Mohapatra G., Louis D.N. In situ analysis of integrin and growth factor receptor signaling pathways in human glioblastomas suggests overlapping relationships with focal adhesion kinase activation. Am. J. Pathol. 2005, 167:1379.
127. Rooprai H.K., Vanmeter T., Panou C., Schnull S., Trillo-Pazos G., Davies D., Pilkington G.J. The role of integrin receptors in aspects of glioma invasion in vitro. Int. J. Dev. Neurosci. 1999, 17:613.
128. Paulus W., Baur I., Schuppan D., Roggendorf W. Characterization of integrin receptors in normal and neoplastic human brain. Am. J. Pathol. 1993, 143:154.
129. Brown M.C., Staniszewska I., Lazarovici P., Tuszynski G.P., Del Valle L., Marcinkiewicz C. Regulatory effect of nerve growth factor in alpha9beta1 integrin-dependent progression of glioblastoma. Neuro Oncol. 2008, 10:968.
130. Gingras M.C., Roussel E., Bruner J.M., Branch C.D., Moser R.P. Comparison of cell adhesion molecule expression between glioblastoma multiforme and autologous normal brain tissue. J. Neuroimmunol. 1995, 57:143.
131. Schnell O., Krebs B., Wagner E., Romagna A., Beer A.J., Grau S.J., Thon N., Goetz C., Kretzschmar H.A., Tonn J.C., Goldbrunner R.H. Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature. Brain Pathol 2008, 18:378.
132. Gladson C.L. Expression of integrin alpha v beta 3 in small blood vessels of glioblastoma tumors. J. Neuropathol. Exp. Neurol. 1996, 55:1143.
133. Rieken S., Habermehl D., Mohr A., Wuerth L., Lindel K., Weber K., Debus J., Combs S.E. Targeting alphanubeta3 and alphanubeta5 inhibits photon-induced hypermigration of malignant glioma cells. Radiat. Oncol. 2011, 6:132.
134. Abdollahi A., Griggs D.W., Zieher H., Roth A., Lipson K.E., Saffrich R., Grone H.J., Hallahan D.E., Reisfeld R.A., Debus J., Niethammer A.G., Huber P.E. Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin. Cancer Res. 2005, 11:6270.
135. Wild-Bode C., Weller M., Wick W. Molecular determinants of glioma cell migration and invasion. J. Neurosurg. 2001, 94:978.
136. Tonn J.C., Wunderlich S., Kerkau S., Klein C.E., Roosen K. Invasive behaviour of human gliomas is mediated by interindividually different integrin patterns. Anticancer. Res. 1998, 18:2599.
137. Fukushima Y., Ohnishi T., Arita N., Hayakawa T., Sekiguchi K. Integrin alpha3beta1-mediated interaction with laminin-5 stimulates adhesion, migration and invasion of malignant glioma cells. Int. J. Cancer 1998, 76:63.
138. Paulus W., Tonn J.C. Basement membrane invasion of glioma cells mediated by integrin receptors. J. Neurosurg. 1994, 80:515.
139. Ogier C., Bernard A., Chollet A.M., Led T., Hanessian S., Charton G., Khrestchatisky M., Rivera S. Matrix metalloproteinase-2 (MMP-2) regulates astrocyte motility in connection with the actin cytoskeleton and integrins. Glia 2006, 54:272.
140. Chintala S.K., Sawaya R., Gokaslan Z.L., Rao J.S. Modulation of matrix metalloprotease-2 and invasion in human glioma cells by alpha 3 beta 1 integrin. Cancer Lett. 1996, 103:201.
141. Cordes N., Seidler J., Durzok R., Geinitz H., Brakebusch C. Beta1-integrin-mediated signaling essentially contributes to cell survival after radiation-induced genotoxic injury. Oncogene 2006, 25:1378.
142. Rieken S., Habermehl D., Wuerth L., Brons S., Mohr A., Lindel K., Weber K., Haberer T., Debus J., Combs S.E. Carbon ion irradiation inhibits glioma cell migration through downregulation of integrin expression. Int. J. Radiat. Oncol. Biol. Phys. 2011, 83:394.
143. Goetze K., Scholz M., Taucher-Scholz G., Mueller-Klieser W. The impact of conventional and heavy ion irradiation on tumor cell migration in vitro. Int. J. Radiat. Biol. 2007, 83:889.
144. Beadle C., Assanah M.C., Monzo P., Vallee R., Rosenfeld S.S., Canoll P. The role of myosin II in glioma invasion of the brain. Mol. Biol. Cell 2008, 19:3357.
145. Caspani E.M., Echevarria D., Rottner K., Small J.V. Live imaging of glioblastoma cells in brain tissue shows requirement of actin bundles for migration. Neuron Glia Biol. 2006, 2:105.
146. Weeks A., Okolowsky N., Golbourn B., Ivanchuk S., Smith C., Rutka J.T. ECT2 and RASAL2 mediate mesenchymal-amoeboid transition in human astrocytoma cells. Am. J. Pathol. 2012, 181:662.
147. Oppel F., Muller N., Schackert G., Hendruschk S., Martin D., Geiger K.D., Temme A. SOX2-RNAi attenuates S-phase entry and induces RhoA-dependent switch to protease-independent amoeboid migration in human glioma cells. Mol. Cancer 2011, 10:137.
148. Frankel P., Pellet-Many C., Lehtolainen P., D'Abaco G.M., Tickner M.L., Cheng L., Zachary I.C. Chondroitin sulphate-modified neuropilin 1 is expressed in human tumour cells and modulates 3D invasion in the U87MG human glioblastoma cell line through a p130Cas-mediated pathway. EMBO Rep. 2008, 9:983.
149. Ridley A.J., Schwartz M.A., Burridge K., Firtel R.A., Ginsberg M.H., Borisy G., Parsons J.T., Horwitz A.R. Cell migration: integrating signals from front to back. Science 2003, 302:1704.
150. Lauffenburger D.A., Horwitz A.F. Cell migration: a physically integrated molecular process. Cell 1996, 84:359.
151. Friedl P., Wolf K. Proteolytic interstitial cell migration: a five-step process. Cancer Metastasis Rev. 2009, 28:129.
152. Lammermann T., Sixt M. Mechanical modes of 'amoeboid' cell migration. Curr. Opin. Cell Biol. 2009, 21:636.
153. Bauman G.S., Fisher B.J., McDonald W., Amberger V.R., Moore E., Del Maestro R.F. Effects of radiation on a three-dimensional model of malignant glioma invasion. Int. J. Dev. Neurosci. 1999, 17:643.
154. Kim H.D., Guo T.W., Wu A.P., Wells A., Gertler F.B., Lauffenburger D.A. Epidermal growth factor-induced enhancement of glioblastoma cell migration in 3D arises from an intrinsic increase in speed but an extrinsic matrix- and proteolysis-dependent increase in persistence. Mol. Biol. Cell 2008, 19:4249.
155. Stahler C., Roth J., Cordes N., Taucher-Scholz G., Mueller-Klieser W. Impact of carbon ion irradiation on epidermal growth factor receptor signaling and glioma cell migration in comparison to conventional photon irradiation. Int. J. Radiat. Biol. 2013, 89:454-461.
156. Joo K.M., Kim J., Jin J., Kim M., Seol H.J., Muradov J., Yang H., Choi Y.L., Park W.Y., Kong D.S., Lee J.I., Ko Y.H., Woo H.G., Lee J., Kim S., Nam D.H. Patient-specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ. Cell Rep. 2013, 3:260.
157. Schultz C., Lemke N., Ge S., Golembieski W.A., Rempel S.A. Secreted protein acidic and rich in cysteine promotes glioma invasion and delays tumor growth in vivo. Cancer Res. 2002, 62:6270.
158. Dai C., Holland E.C. Glioma models. Biochim. Biophys. Acta 2001, 1551:M19.
159. Zhai G.G., Malhotra R., Delaney M., Latham D., Nestler U., Zhang M., Mukherjee N., Song Q., Robe P., Chakravarti A. Radiation enhances the invasive potential of primary glioblastoma cells via activation of the Rho signaling pathway. J. Neurooncol. 2006, 76:227.
160. Monferran S., Skuli N., Delmas C., Favre G., Bonnet J., Cohen-Jonathan-Moyal E., Toulas C. Alphavbeta3 and alphavbeta5 integrins control glioma cell response to ionising radiation through ILK and RhoB. Int. J. Cancer 2008, 123:357.
161. Bauman G.S., MacDonald W., Moore E., Ramsey D.A., Fisher B.J., Amberger V.R., Del Maestro R.M. Effects of radiation on a model of malignant glioma invasion. J. Neurooncol. 1999, 44:223.
162. Engebraaten O., Schwachenwald R., Valen H., Bjerkvig R., Laerum O.D., Backlund E.O. Effects of high and low single dose irradiation on glioma spheroid invasion into normal rat brain tissue in vitro. Anticancer. Res. 1992, 12:1501.
163. Sarkaria J.N., Kitange G.J., James C.D., Plummer R., Calvert H., Weller M., Wick W. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin. Cancer Res. 2008, 14:2900.
164. Noha M., Yoshida D., Watanabe K., Teramoto A. Suppression of cell invasion on human malignant glioma cell lines by a novel matrix-metalloproteinase inhibitor SI-27: in vitro study. J. Neurooncol. 2000, 48:217.
165. Tonn J.C., Kerkau S., Hanke A., Bouterfa H., Mueller J.G., Wagner S., Vince G.H., Roosen K. Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro. Int. J. Cancer 1999, 80:764.
166. Price A., Shi Q., Morris D., Wilcox M.E., Brasher P.M., Rewcastle N.B., Shalinsky D., Zou H., Appelt K., Johnston R.N., Yong V.W., Edwards D., Forsyth P. Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340. Clin. Cancer Res. 1999, 5:845.
167. Groves M.D., Puduvalli V.K., Hess K.R., Jaeckle K.A., Peterson P., Yung W.K., Levin V.A. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J. Clin. Oncol. 2002, 20:1383.
168. Tabatabai G., Weller M., Nabors B., Picard M., Reardon D., Mikkelsen T., Ruegg C., Stupp R. Targeting integrins in malignant glioma. Target. Oncol. 2010, 5:175.
169. Reardon D.A., Nabors L.B., Stupp R., Mikkelsen T. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert. Opin. Investig. Drugs 2008, 17:1225.
170. Maurer G.D., Tritschler I., Adams B., Tabatabai G., Wick W., Stupp R., Weller M. Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. Neuro. Oncol. 2009, 11:747.
171. Mikkelsen T., Brodie C., Finniss S., Berens M.E., Rennert J.L., Nelson K., Lemke N., Brown S.L., Hahn D., Neuteboom B., Goodman S.L. Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. Int. J. Cancer 2009, 124:2719.
172. Reardon D.A., Fink K.L., Mikkelsen T., Cloughesy T.F., O'Neill A., Plotkin S., Glantz M., Ravin P., Raizer J.J., Rich K.M., Schiff D., Shapiro W.R., Burdette-Radoux S., Dropcho E.J., Wittemer S.M., Nippgen J., Picard M., Nabors L.B. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J. Clin. Oncol. 2008, 26:5610.
173. Nabors L.B., Mikkelsen T., Rosenfeld S.S., Hochberg F., Akella N.S., Fisher J.D., Cloud G.A., Zhang Y., Carson K., Wittemer S.M., Colevas A.D., Grossman S.A. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J. Clin. Oncol. 2007, 25:1651.
174. Nabors L.B., Mikkelsen T., Hegi M.E., Ye X., Batchelor T., Lesser G., Peereboom D., Rosenfeld M.R., Olsen J., Brem S., Fisher J.D., Grossman S.A. A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer 2012, 118:5601.
175. Stupp R., Hegi M.E., Neyns B., Goldbrunner R., Schlegel U., Clement P.M., Grabenbauer G.G., Ochsenbein A.F., Simon M., Dietrich P.Y., Pietsch T., Hicking C., Tonn J.C., Diserens A.C., Pica A., Hermisson M., Krueger S., Picard M., Weller M. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 2010, 28:2712.
176. Combs S.E., Zipp L., Rieken S., Habermehl D., Brons S., Winter M., Haberer T., Debus J., Weber K.J. In vitro evaluation of photon and carbon ion radiotherapy in combination with chemotherapy in glioblastoma cells. Radiat. Oncol. 2012, 7:9.
177. Combs S.E., Bohl J., Elsasser T., Weber K.J., Schulz-Ertner D., Debus J., Weyrather W.K. Radiobiological evaluation and correlation with the local effect model (LEM) of carbon ion radiation therapy and temozolomide in glioblastoma cell lines. Int. J. Radiat. Biol. 2009, 85:126.
178. Mizoe J.E., Tsujii H., Hasegawa A., Yanagi T., Takagi R., Kamada T., Tsuji H., Takakura K. Phase I/II clinical trial of carbon ion radiotherapy for malignant gliomas: combined X-ray radiotherapy, chemotherapy, and carbon ion radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2007, 69:390.
179. Combs S.E., Burkholder I., Edler L., Rieken S., Habermehl D., Jakel O., Haberer T., Haselmann R., Unterberg A., Wick W., Debus J. Randomised phase I/II study to evaluate carbon ion radiotherapy versus fractionated stereotactic radiotherapy in patients with recurrent or progressive gliomas: the CINDERELLA trial. BMC Cancer 2010, 10:533.
180. Combs S.E., Kieser M., Rieken S., Habermehl D., Jakel O., Haberer T., Nikoghosyan A., Haselmann R., Unterberg A., Wick W., Debus J. Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trial. BMC Cancer 2010, 10:478.